Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Characterizing the role of stem cell-derived beta-like cells in the progression of diabetic nephropathy
EF 2017-18
Résumé
Diabetic kidney disease (DKD) is the most common cause of end-stage renal disease, yet effective treatments for this disorder are lacking. One potential therapy for DKD is achieving excellent blood glucose control using pancreas or islet transplantation. However shortage of donors limits this approach. Stem cell-derived pancreatic beta-like cells (BLCs) could potentially be used as a surrogate for organ transplantation, as these cells have demonstrated the ability to normalize blood glucose when transplanted into diabetic mice. Generation of off-the-shelf BLCs could thus provide a scalable and effective therapy for diabetes. However, the effect of BLCs on complications of diabetes, including DKD, remains unknown. Moreover, BLCs derived in this way will require immunosuppression to prevent rejection, and the effects of this on kidney function are equally unclear. My hypothesis is that DKD can be attenuated by BLC transplantation in the presence of immunosuppression. To study this, my aims are twofold: 1) to determine whether BLCs can survive and function in diabetic hosts with immunosuppression, and 2) to determine the effect of immunosuppression and BLCs on kidney disease. To test this hypothesis, I will use an immunocompetent mouse model prone to developing diabetes and kidney disease. These mice (and relevant controls) will be treated with BLCs and immunosuppression. Metabolic control (weight, blood pressure, blood glucose levels), and kidney structure and function will be assessed for 16 weeks after transplantation.The clinical role of BLCs will ultimately be dictated by its risks and benefits. Determining the effect of BLCs and immunosuppression on kidney function will thus be a major step forward for clinical translation.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386351
Name
Misra Paraish S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing the role of stem cell-derived beta-like cells in the progression of diabetic nephropathy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Beta Cells; Costimulation Blockade; Diabetic Nephropathy; Immunosuppression; Rejection; Stem Cells
Abstract
Diabetic kidney disease (DKD) is the most common cause of end-stage renal disease, yet effective treatments for this disorder are lacking. One potential therapy for DKD is achieving excellent blood glucose control using pancreas or islet transplantation. However shortage of donors limits this approach. Stem cell-derived pancreatic beta-like cells (BLCs) could potentially be used as a surrogate for organ transplantation, as these cells have demonstrated the ability to normalize blood glucose when transplanted into diabetic mice. Generation of off-the-shelf BLCs could thus provide a scalable and effective therapy for diabetes. However, the effect of BLCs on complications of diabetes, including DKD, remains unknown. Moreover, BLCs derived in this way will require immunosuppression to prevent rejection, and the effects of this on kidney function are equally unclear. My hypothesis is that DKD can be attenuated by BLC transplantation in the presence of immunosuppression. To study this, my aims are twofold: 1) to determine whether BLCs can survive and function in diabetic hosts with immunosuppression, and 2) to determine the effect of immunosuppression and BLCs on kidney disease. To test this hypothesis, I will use an immunocompetent mouse model prone to developing diabetes and kidney disease. These mice (and relevant controls) will be treated with BLCs and immunosuppression. Metabolic control (weight, blood pressure, blood glucose levels), and kidney structure and function will be assessed for 16 weeks after transplantation.The clinical role of BLCs will ultimately be dictated by its risks and benefits. Determining the effect of BLCs and immunosuppression on kidney function will thus be a major step forward for clinical translation.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Misra, Paraish S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~